Original articleIncreased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS)
Section snippets
Patients and control subjects
We performed a cross-sectional case-control study at the Hospital Universitario Marqués de Valdecilla (Santander, Spain). From February 2014 to March 2015, consecutive Caucasian patients with an appropriate diagnosis of HS were recruited from our dermatology outpatient clinic. The diagnosis of HS was made by dermatologists. Diagnostic criteria were established as follows, and all 3 criteria were necessary to establish the diagnosis: (1) presence of typical lesions: nodules (inflammatory or
Demographic, clinical, and laboratory data
A total of 68 patients with HS and 136 healthy control subjects were studied. The main demographic and clinical characteristics are summarized in Table II. The mean age did not significantly differ between the patients with HS and control subjects. The gender distribution for both groups was similar. According to the HS-PGA, 29 patients (42.6%) were classified as having minimal-mild HS (HS-PGA score <3) and the remaining 39 (57.4%) as having moderate-severe/very severe HS (HS-PGA score ≥3). The
Discussion
The results of this study show that patients with HS without clinically evident CVD have a higher prevalence of subclinical atherosclerosis by exhibiting a greater cIMT than control subjects matched for age and sex. Carotid plaques were also more frequently observed in patients with HS than in control subjects. However, this difference was only statistically significant between the subgroup of patients with moderate-severe/very severe HS (HS-PGA score ≥3) and the control group. In fact, we have
References (34)
- et al.
The prevalence of hidradenitis suppurativa and its potential precursor lesions
J Am Acad Dermatol
(1996) - et al.
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
J Am Acad Dermatol
(2008) - et al.
Pathophysiology of hidradenitis suppurativa: an update
J Am Acad Dermatol
(2015) - et al.
Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis
J Am Acad Dermatol
(2014) - et al.
Systemic associations of hidradenitis suppurativa
J Am Acad Dermatol
(2015) - et al.
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa
J Am Acad Dermatol
(2014) - et al.
Psoriasis: a skin disease associated with increased cardiovascular risk
Actas Dermosifiliogr
(2012) - et al.
Increased subclinical atherosclerosis in patients with chronic plaque psoriasis
Atherosclerosis
(2014) - et al.
Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: is psoriasis associated with atherosclerosis?
J Am Acad Dermatol
(2014) - et al.
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
Lancet
(1992)
Evaluation of subclinical atherosclerosis in Egyptian psoriatic patients
J Saudi Heart Assoc
Hidradenitis suppurativa
J Eur Acad Dermatol Venereol
Clinical practice. Hidradenitis suppurativa
N Engl J Med
Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
J Am Acad Dermatol
Hidradenitis suppurativa: the role of immune dysregulation
Int J Dermatol
Increased serum tumor necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumor necrosis factor-alpha agents?
Acta Derm Venereol
Elevated levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
Br J Dermatol
Cited by (0)
Drs González-Gay and Blanco share senior authorship.
Supported by an unrestricted grant from Abbvie Inc.
Disclosure: Dr González-Gay received grant funding from Abbvie. Drs González-López, Hernández, Lacalle, Mata, López-Escobar, López-Mejías, Corrales, González-Vela, and Blanco, Ms Portilla, and Ms Fuentevilla have no conflicts of interest to declare. The opinions expressed in this article are those of the authors and do not necessarily represent those of Abbvie Inc.